Alcon (ALC.SW) Dionica Cijena

Alcon Cijena

SIX·ZATVORENO
63,85
​
Tržište zatvoreno

Prihod je rastao 4,9 % godišnje u posljednjih 10 godina na 8,86 milijardi USD. Zarada po dionici rasla je 12,7 % godišnje u posljednjih 10 godina. neto marža tvrtke Alcon sada iznosi 9,4 %, porasla s 4,5 % prije nekoliko godina. Alcon trenutačno nudi dividendni prinos od oko 0,44 %. Omjer isplate je oko 20 % dobiti. Dividenda je rasla 29,4 % godišnje u posljednjih 4 godina. Medijan analitičke ciljane cijene je 100,35 USD, odnosno iznad trenutačnu cijenu za 57,2 %. Od 20 analitičara 15 preporučuje kupnju — ukupni konsenzus je Kupi.

Cijena dionice Alcon

Pristupite ovim podacima putem Eulerpool API-ja

Dioncia Alcon i analiza dionice

Alcon AG je vodeća tvrtka u oftalmologiji s više od 70 godina iskustva u ovoj industriji. Tvrtku su 1945. godine osnovali Robert Alexander i William Conner, a sjedište joj se nalazi u Ženevi, Švicarska. Alcon AG dio je Novartis Grupe od 2019. godine i lider je u proizvodnji oftalmoloških proizvoda. Poslovni model Alcon AG-a temelji se na proizvodnji i prodaji oftalmoloških proizvoda. Tvrtka nudi medicinske proizvode poput kontaktnih leća, kirurških instrumenata, kapi za oči i intraokularnih leća. Alcon AG specijaliziran je za razvoj proizvoda koji se mogu koristiti za liječenje različitih očnih bolesti. Tvrtka pruža širok raspon proizvoda koji koriste oftalmolozima i optičarima. Različite divizije Alcon AG-a uključuju proizvode za njegu očiju, kirurške proizvode i dijagnostičke proizvode. Proizvodi za njegu očiju, kao što su kontaktne leće, potrošačima nude siguran i jednostavan način ispravljanja vida. Kirurški proizvodi obuhvaćaju širok raspon instrumenata koji se koriste u operacijama oka. Dijagnostički proizvodi pomažu u identificiranju očnih bolesti i podržavaju liječenje. Alcon AG specijaliziran je za razvoj proizvoda za liječenje očnih bolesti. To uključuje stanja poput katarakte, glaukoma i dobne makularne degeneracije. Tvrtka nudi različite proizvode koji se mogu koristiti za ta stanja, poput kapi za oči koje smanjuju povišeni intraokularni tlak kod glaukoma. Također je razvila širok raspon proizvoda za refraktivnu korekciju, omogućujući ljudima da poboljšaju vid. Alcon AG usko surađuje s vodećim oftalmolozima i optičarima kako bi optimizirao razvoj svojih proizvoda. Ova bliska suradnja osigurava da proizvodi Alcon AG-a zadovoljavaju potrebe pacijenata i pružaju im visoku sigurnost i učinkovitost. Inovativnim proizvodima i tehnologijama Alcon AG nastoji poboljšati kvalitetu života pacijenata i pružiti im optimalnu skrb i liječenje. U cjelini, Alcon AG je vodeća tvrtka u oftalmologiji koja svojim kupcima nudi širok raspon inovativnih i visokokvalitetnih proizvoda. Od dijagnoze do skrbi i kirurških intervencija, ponuda proizvoda Alcon AG-a pokriva sve područje oftalmologije. Tvrtka je poznata po istraživanju i razvoju te kontinuirano radi na napretku oftalmologije. Kroz stalne inovacije i orijentaciju prema kupcima, Alcon AG učvrstio je snažan položaj u zdravstvenoj industriji i ubuduće će predstavljati nove proizvode i tehnologije.

Često postavljana pitanja o dionici Alcon

The business model of Alcon AG centers around providing innovative eye care solutions and products. As a globally recognized company, Alcon AG specializes in developing, manufacturing, and distributing a wide range of ophthalmic surgical equipment, pharmaceuticals, and consumer eye care products. Their offerings include contact lenses, surgical equipment for cataract and refractive surgeries, as well as prescription and over-the-counter eye care products. With a strong focus on research and development, Alcon AG aims to continuously improve eye health outcomes and enhance vision quality for individuals around the world.

Alcon AG is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Alcon AG in the market are Johnson & Johnson Vision, Bausch Health Companies Inc., and Novartis AG.

Alcon AG is a renowned company with a rich history and background. Established in XYZ, Alcon AG has become a leading player in the industry. The company specializes in XYZ products and services, catering to a wide range of customers worldwide. Over the years, Alcon AG has achieved significant milestones and global recognition for its innovative solutions and exceptional quality. With a strong commitment to excellence, Alcon AG continues to expand its presence and investment in research and development. With a solid track record, Alcon AG has remained a trusted choice for investors seeking growth and reliability in the market.

Alcon AG, a renowned stock, has achieved significant milestones throughout its journey. The company has successfully introduced groundbreaking products and technologies in the field of eye care. Alcon AG's major achievements include the development of revolutionary intraocular lenses (IOLs) that have enhanced vision correction and improved patients' quality of life. Additionally, the company pioneered innovative surgical equipment and techniques, such as advanced phacoemulsification devices, revolutionizing cataract surgery. Alcon AG has dedicated itself to providing cutting-edge ophthalmic solutions, elevating the standards of eye care globally. With its impressive track record, Alcon AG stands out as a leading entity within the stock market.

Alcon AG primarily operates in various countries and regions worldwide. With its global presence, the company has established a strong foothold in key markets across the Americas, Europe, Asia, and Africa. Alcon AG's extensive reach includes countries such as the United States, Germany, Switzerland, France, China, Japan, Australia, South Africa, and many others. The company's strategic expansion allows it to cater to a diverse clientele, providing innovative eye care products and services internationally.

Alcon AG represents a strong commitment to values and a clear corporate philosophy. The company prioritizes integrity, innovation, and excellence in all aspects of its operations. Alcon is dedicated to improving vision care and providing high-quality eye care products and services to its customers. With a focus on continuous research and development, Alcon aims to deliver cutting-edge solutions for eye health. By upholding these values and embracing a forward-thinking approach, Alcon AG sets itself apart as a trusted and leading player in the field of ophthalmic innovation.

Analitičari trenutačno postavljaju prosječnu ciljanu cijenu 100,85 USD za dionicu Alcon (medijan: 100,35 USD), što znači +57,9 % u odnosu na zadnju cijenu. Konsenzus se temelji na 20 ocjena.

20 analitičara trenutačno ocjenjuje dionicu Alcon: 16 preporučuje kupnju, 2 držanje i 2 prodaju. Za 2026 analitičari očekuju da Alcon ostvari prihod 10,82 milijardi USD i zaradu po dionici 3,44 USD.

Po trenutačnom tečaju dionica Alcon kotira 56,98 EUR (63,85 USD).

Dionica Alcon (ALC.SW) uvrštena je na 7 burze, uključujući: NYSE (ALC), London (0A0D.L), SIX (Zürich) (ALC.SW), Frankfurt (2U3.F), München (2U3.MU), Düsseldorf (2U3.DU), Hamburg (2U3.HM).

Alcon AG is a global company that offers a wide range of eye care products for patients and medical professionals. The company specializes in developing and manufacturing innovative solutions for optimal vision and eye health. Alcon operates in over 75 countries worldwide. Alcon has five main business areas: Surgery, Vision Care, Pharma, Ophthalmic Devices, and Ophthalmic Instruments. The Surgery division specializes in surgical procedures such as cataract surgery and retinal surgery. The Vision Care division deals with contact lenses, glasses, and other vision correction products. The Pharma division includes medications for treating eye diseases such as glaucoma and allergic conjunctivitis. The Ophthalmic Devices and Ophthalmic Instruments divisions specialize in medical accessories and instruments. Alcon's most well-known product is the Air Optix contact lens, available in various designs and materials, which allows for longer wear time. The Dailies contact lens line and the TrueTear therapy for dry eyes are also popular Alcon products. Alcon has also developed some innovative technologies, including the ORA System, which allows for more precise measurements of eye data during cataract surgery, and the WaveLight Refractive Suite for correcting refractive errors such as myopia, hyperopia, and astigmatism. Another important product from Alcon is Restasis, a medication for treating dry eyes. It is the first FDA-approved medication to stimulate natural tear production. Alcon's business model is based on innovation and quality. The company heavily invests in research and development to develop the eye care solutions of the future. Alcon also has a strong presence in the education and training of eye doctors and other medical professionals. The company offers training and continuing education to keep doctors and professionals up to date and help them utilize Alcon's innovative technologies and products. Alcon also has a strong online presence and offers a wide range of digital resources, including online training, resources for medical professionals and patients, and videos on eye care products and technologies. Overall, Alcon is a leading company in the eye care industry that focuses on innovation and quality. With a wide range of products and services and a strong presence in medical education and training, Alcon is well positioned to continue growing and improving eye health and vision worldwide.

Prihod od očekivane od Alcon iznosi 10,82 milijardi USD. Ova brojka temelji se na trenutnim financijskim podacima i odražava poslovnu uspješnost poduzeća.

Dobit od očekivane od Alcon iznosi 1,69 milijardi USD. Neto dobit pokazuje profitabilnost poduzeća nakon odbitka svih troškova.

Omjer cijene i zarade (KGV) od Alcon trenutno je 18,57. KGV uspoređuje trenutnu cijenu dionice sa zaradom po dionici i pomaže ulagačima da procijene vrednovanje dionice Alcon.

Omjer cijene i prihoda (KUV) od Alcon trenutno je 2,91. KUV uspoređuje tržišnu kapitalizaciju s godišnjim prihodom i služi kao pokazatelj vrednovanja dionice Alcon.

Eulpool Quality Score za Alcon je 5/10.

ISIN od Alcon je CH0432492467. ISIN (International Securities Identification Number) je globalno jedinstvena identifikacija za vrijednosne papire.

WKN od Alcon je A2PDXE. WKN (Wertpapierkennnummer) je šestoznačni njemački broj za identifikaciju vrijednosnih papira.

Ticker od Alcon je ALC.SW. Simbol tickera koristi se za trgovanje dionicama Alcon na burzi.

Fer vrijednostTerminal
59,38 USD
Pre-/PodcijenjenostTerminal
Pravedno vrjednovano
Sektor
Industrija
Medicinska Oprema i Zalihe
Broj dionica
zaposlenici
Prihod po zaposleniku
399.922,32 USD
Prosječni rast prihoda Ø5 godina
EBIT rast Ø5 godina
Dobičak-Rast Ø5 godina
Web stranica alcon.com
Valuta
USD
IPO
9. tra 2019.
ISIN
CH0432492467
CUSIP
H01301128
SEDOL
BJT1GR5
Tržišna kapitalizacija
Raspon od 52 tjedna
AAQS
5 / 10
PEG omjer
3,72
KGVe 2026
18,72
KGVe 2027
16,52
KGVe 2028
14,63
KGVe 2029
12,79
KGVe 2030
11,56
P/S
KUVe
2,91
EV/EBIT
30,06
P/B omjer
1,77
ROCE
ROIC
3,61 %
Dividenda
Dividendski prinos
0,44 %
Procj. dividendni prinos
0,44 %
Omjer isplate
19,85 %
Prosječni rast dividendi u 5 godina
6,96 %
Dividende po godini
1
Dividenda plaćena od
5 godina
Dividenda se ne smanjuje od
0 godina
Dividenda povećava od
0 godina
Porez na dividende
35,00 %
Zadnje ažurirano 10. lis 2026. 12:57

Alcon Simbol

DÜSSELDORF · 2U3.DUFRANKFURT · 2U3.FHAMBURG · 2U3.HMLONDON · 0A0D.LMÜNCHEN · 2U3.MUNEW YORK · ALCSIX · ALC.SW

Alcon FIGI

ALC:SW · BBG00NPWGYJ9ALC:SE · BBG00NPWGYL6ALC:BW · BBG00NPWGYQ1ALC:US · BBG00NPWH832ALC:UA · BBG00NPWH841ALC:UC · BBG00NPWH850ALC:UN · BBG00NPWH878ALC:UP · BBG00NPWH887ALC:UB · BBG00NPWH8B3ALC:UT · BBG00NPWH8C2ALC:UM · BBG00NPWH8D1ALC:UX · BBG00NPWH8F9